Sign Out
Hepatic Effects: Therapy with Rosuvastatin and other statins has been associated with increases in serum aminotransferase (transaminase) concentrations. Therefore, the manufacturer recommends that liver function tests be performed before and at 12 weeks after initiation of Rosuvastatin therapy or any increase in dosage and periodically (e.g., semiannually) thereafter. Patients who develop increased serum transaminase concentrations or manifestations of liver disease should have frequent liver function tests performed thereafter until the abnormalities return to normal.
Jaundice has been reported rarely with Rosuvastatin therapy.
Musculoskeletal Effects: Myopathy has been reported occasionally (up to 0.1%) with Rosuvastatin therapy. Rhabdomyolysis with or without acute renal failure secondary to myoglobinuria has been reported rarely with statin therapy, including with Rosuvastatin. Rhabdomyolysis occurs more frequently in patients receiving Rosuvastatin 40 mg daily compared with lower dosages. However, it does not appear that the risk of rhabdomyolysis is greater with Rosuvastatin than with other statins.
Continue with Google